A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Study acronym: CANTOR
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Trial sites reduced: 76 → 56 locations
    • Enrollment target: estimated 80 to confirmed 82
    • Eligibility criteria expanded, about 36 words
    • Study description expanded, about 2 words
  2. Site details revised at 10 of 76 sitesv13
  3. Enrollment reduced: 120 → 80 participants
    • Primary completion pushed from May 31, 2027 to Jun 30, 2027
    • Study completion pushed from Jun 7, 2028 to Sep 29, 2028
    • Site details revised at 4 of 76 sites
    v12
  4. Re-verified, no change to tracked fieldsv11
  5. Site details revised at 4 of 76 sitesv10
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Site details revised at 1 of 76 sitesv8
  3. Site details revised at 18 of 76 sitesv7
  4. Study sites: 75 to 76
    • Primary completion date: Mar 24, 2027 to May 31, 2027
    • Study completion date: Jan 11, 2028 to Jun 7, 2028
    v6
  5. Study completion date: Jan 12, 2028 to Jan 11, 2028
    • Site details revised at 7 of 75 sites
    v5
  6. Site details revised at 3 of 75 sitesv4
  7. Study sites: 59 to 75v3
  8. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 59
    • Primary completion date: Mar 31, 2027 to Mar 24, 2027
    • Study completion date: Jan 19, 2028 to Jan 12, 2028
    • Start date changed from estimate of Mar 19, 2025 to Mar 12, 2025
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
734 trials monitored
See 61 trials at risk
Colorectal Cancer
3,418 trials monitored
See 162 trials at risk
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Trial Details
NCT Number NCT06792695
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms, Neoplasm Metastasis
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov